A2 share price frenzy – but is the US formula market worth it?

A2 share price frenzy – but is the US formula market worth it?
The American dream may not be worth it for A2. (Image: Getty)
Jenny Ruth
Some investors believe accessing the US infant formula market would be a big deal for Fonterra and the A2 Milk Company, and trading in A2’s shares last week highlighted that fact.An Australian Financial Review (AFR) journalist got a little over her skis on Tuesday and published a story saying A2 could get US Food & Drug Administration (FDA) approval “as soon as this week”.Both Fonterra and A2 have been waiting for this approval since they applied in late May after the FDA made public it was looking to facilitate infant for...

More Primary Sector

Bell Potter boosts Santana target price 53.5%
Primary Sector

Bell Potter boosts Santana target price 53.5%

Aussie brokers increasingly like the look of a low-cost, high yield Otago gold play.

Pattrick Smellie 19 Apr 2024
Anna Palairet appointed Fonterra's chief operating officer
Primary Sector

Anna Palairet appointed Fonterra's chief operating officer

Having acted in the role since June last year, she replaces Fraser Whineray.

Riley Kennedy 19 Apr 2024
Progress takes more than Groundhog Day rhetoric
Primary Sector

Julia Jones: Progress takes more than Groundhog Day rhetoric

There seems to be a noticeable lack of innovation in NZ's red meat export industry.

Julia Jones 19 Apr 2024
Tough season for Terra Vitae Vineyards
Primary Sector

Tough season for Terra Vitae Vineyards

The yield from this year's harvest was 20% below the budgeted amount.

Rebecca Howard 19 Apr 2024